Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).

Date publication

novembre 2020

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno , Pr PIVOT Xavier

Tous les auteurs :
Cottu P, Coudert B, Perol D, Doly A, Manson J, Aujoulat O, Barletta H, Chalabi N, Samelson L, Pivot X

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33176232

Résumé

There is a growing need for real-world data on cancer treatments usage, especially to assess compliance with recommendations. We developed a French project using hospital data to analyse evolution in the therapeutic strategies implemented in patients with human epidermal growth factor receptor 2 (HER2)-overexpressed (HER2+) breast cancer (BC) and exposed to injectable HER2-targeted therapies, i.e. trastuzumab, pertuzumab or trastuzumab emtansine (T-DM1).

Mots clés

Breast cancer, HER2, Pertuzumab, Retrospective real-world data study, Trastuzumab, Trastuzumab emtansine

Référence

Eur J Cancer. 2020 Nov 8;141:209-217